Last reviewed · How we verify
inotropes therapy
Inotropes increase the force of cardiac muscle contraction to improve heart output in patients with reduced cardiac function.
Inotropes increase the force of cardiac muscle contraction to improve heart output in patients with reduced cardiac function. Used for Acute decompensated heart failure, Cardiogenic shock, Low cardiac output states.
At a glance
| Generic name | inotropes therapy |
|---|---|
| Also known as | Dopamine, Olprinone, Levosimendan |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Inotropic agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Inotropic agents work by enhancing myocardial contractility through various mechanisms, such as increasing intracellular calcium availability or activating adrenergic receptors. This results in stronger heart contractions and improved cardiac output, particularly beneficial in acute decompensated heart failure, cardiogenic shock, or post-operative cardiac dysfunction.
Approved indications
- Acute decompensated heart failure
- Cardiogenic shock
- Low cardiac output states
Common side effects
- Tachycardia
- Arrhythmias
- Hypotension
- Increased myocardial oxygen demand
Key clinical trials
- Hypotension Prediction Index (HPI) and Assisted Fluid Management (AFM) for Perioperative Hemodynamic Optimization in Patients Under General Anesthesia (NA)
- Levosimendan in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children Hospital
- Preventive Strategies for Early and Late Complications of Leptospirosis (PHASE2)
- Proactive Hemodynamic Management During Cytoreductive Surgery and HIPEC (NA)
- Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery (NA)
- Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock (NA)
- Cardiogenic Shock Working Group Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: